Decision to list bedaquiline (Sirturo) and siltuximab (Sylvant) for rare disorders Thursday, 12 May 2016

Source: PHARMAC

PHARMAC is pleased to announce the approval of an agreement with Janssen-Cilag Pty Ltd for the listing of bedaquiline (Sirturo) and siltuximab (Sylvant). The agreement is the fourth that PHARMAC has reached with a bidder following a Request for Proposals we ran in 2014, related to the supply of medicines for rare disorders.

This was the subject of a consultation letter dated 12 April 2016, available on PHARMAC's website.

In summary, the effect of the decision is that:

  • bedaquiline (Sirturo) will be funded in the community and in DHB hospitals for treatment of extensively drug resistant tuberculosis (XDR-TB). Listing in the Pharmaceutical Schedule will occur subject to Medsafe approval of the pharmaceutical; and
  • siltuximab (Sylvant) will be funded in the community and in DHB hospitals for treatment of HHV-8 negative idiopathic multicentric Castleman's disease (iMCD). This listing will occur from 1 June 2016.

The decision is as consulted on, with the exception of the following:

  • changes to the Special Authority/restriction applying to bedaquiline;
  • bedaquiline will be listed as XPharm; and
  • changes to the Special Authority/restriction applying to siltuximab.

 

Details of the decision and futher information can be found here